Perineural invasion and associated pain in pancreatic cancer

Nature Reviews Cancer

Volumn 11, Issue 10, 2011, Pages 695-707

  Bapat, Aditi A ^a   Hostetter, Galen ^a   Von Hoff, Daniel D ^a   Han, Haiyong ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARRY 470; ARTEMIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CHEMOKINE RECEPTOR CX3CR1; EPIDERMAL GROWTH FACTOR RECEPTOR; FRACTALKINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; MNAC 13; MUCIN 1; NERVE CELL ADHESION MOLECULE; NERVE GROWTH FACTOR; NEUROPILIN 1; NEUROTROPHIN 3; NEUROTROPHIN 3 RECEPTOR; NEUROTROPHIN 4; NEUROTROPHIN RECEPTOR P75; NEURTURIN; PERSEPHIN; PHA 848125; PLEXIN; PROTEIN TYROSINE KINASE A; PROTEIN TYROSINE KINASE INHIBITOR; RESINIFERATOXIN; SEMAPHORIN 3A; TANEZUMAB; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST;

CANCER INVASION; CANCER PAIN; DRUG TARGETING; HUMAN; INFLAMMATION; METASTASIS; NEUROPATHIC PAIN; NONHUMAN; PANCREAS CANCER; PANCREAS DUCT; PERINEURAL INVASION; PERINEURIUM; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASM INVASIVENESS; PAIN; PANCREATIC NEOPLASMS; PERIPHERAL NERVOUS SYSTEM NEOPLASMS;

EID: 80053162486     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3131     Document Type: Review

References (160)

1. Lesnik, D. J. & Boey, H. P. Perineural invasion of the facial nerve by a cutaneous squamous cell cancer: a case report. Ear Nose Throat J. 83, 826-827 (2004).
2. Liebig, C., Ayala, G., Wilks, J. A., Berger, D. H. & Albo, D. Perineural invasion in cancer: a review of the literature. Cancer 115, 3379-3391 (2009).
3. Demir, I. E. et al. Neural invasion in pancreatic cancer: the past, present and future. Cancers 2, 1513-1527 (2010).
4. Batsakis, J. G. Nerves and neurotropic carcinomas. Ann. Otol. Rhinol. Laryngol. 94, 426-427 (1985).
5. Bockman, D. E., Buchler, M. & Beger, H. G. Interaction of pancreatic ductal carcinoma with nerves leads to nerve damage. Gastroenterology 107, 219-230 (1994). (Pubitemid 24195365)
6. Ceyhan, G. O. et al. Neural invasion in pancreatic cancer: a mutual tropism between neurons and cancer cells. Biochem. Biophys. Res. Commun. 374, 442-447 (2008).
7. Ceyhan, G. O. et al. The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann. Surg. 244, 274-281 (2006). (Pubitemid 44305543)
8. Rodin, A. E., Larson, D. L. & Roberts, D. K. Nature of the perineural space invaded by prostatic carcinoma. Cancer 20, 1772-1779 (1967).
9. Marchesi, F., Piemonti, L., Mantovani, A. & Allavena, P. Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. Cytokine Growth Factor Rev. 21, 77-82 (2010).
10. Ceyhan, G. O., Michalski, C. W., Demir, I. E., Muller, M. W. & Friess, H. Pancreatic pain. Best Pract. Res. Clin. Gastroenterol. 22, 31-44 (2008).
11. Hirai, I. et al. Perineural invasion in pancreatic cancer. Pancreas 24, 15-25 (2002). (Pubitemid 34019655)
12. Liu, B. & Lu, K. Y. Neural invasion in pancreatic carcinoma. Hepatobiliary Pancreat. Dis. Int. 1, 469-476 (2002). (Pubitemid 36748789)
13. Pour, P. M., Bell, R. H. & Batra, S. K. Neural invasion in the staging of pancreatic cancer. Pancreas 26, 322-325 (2003). (Pubitemid 36529955)
14. Ayala, G. E. et al. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res. 64, 6082-6090 (2004). (Pubitemid 39129408)
15. Ayala, G. E. et al. In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate 49, 213-223 (2001). (Pubitemid 33062619)
16. Maru, N., Ohori, M., Kattan, M. W., Scardino, P. T. & Wheeler, T. M. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum. Pathol. 32, 828-833 (2001). (Pubitemid 32803984)
17. Horn, A., Dahl, O. & Morild, I. Venous and neural invasion as predictors of recurrence in rectal adenocarcinoma. Dis. Colon Rectum 34, 798-804 (1991).
18. Huh, J. W., Kim, H. R. & Kim, Y. J. Prognostic value of perineural invasion in patients with stage II colorectal cancer. Ann. Surg. Oncol. 17, 2066-2072 (2010).
19. Pages, F. et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353, 2654-2666 (2005). (Pubitemid 41817714)
20. Cowan, W. K. et al. The pathological and biological nature of screen-detected breast carcinomas: a morphological and immunohistochemical study. J. Pathol. 182, 29-35 (1997). (Pubitemid 27240446)
21. Dunn, M. & Morgan, M. B. Perineural invasion progressing to leptomeningeal carcinomatosis: is the absence of peripheral nerves an important sign? J. Am. Acad. Dermatol. 62, 270-276 (2010).
22. Duraker, N., Sisman, S. & Can, G. The significance of perineural invasion as a prognostic factor in patients with gastric carcinoma. Surg. Today 33, 95-100 (2003). (Pubitemid 36269376)
23. Haddad, R. I. & Shin, D. M. Recent advances in head and neck cancer. N. Engl. J. Med. 359, 1143-1154 (2008).
24. Kurtz, K. A., Hoffman, H. T., Zimmerman, M. B. & Robinson, R. A. Perineural and vascular invasion in oral cavity squamous carcinoma: increased incidence on re-review of slides and by using immunohistochemical enhancement. Arch. Pathol. Lab. Med. 129, 354-359 (2005). (Pubitemid 40343990)
25. Scartozzi, M. et al. Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. Br. J. Cancer 95, 445-449 (2006). (Pubitemid 44232552)
26. Shirai, K. et al. Perineural invasion is a prognostic factor in intrahepatic cholangiocarcinoma. World J. Surg. 32, 2395-2402 (2008).
27. Su, C. H. et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann. Surg. 223, 384-394 (1996).
28. Takahashi, T. et al. Perineural invasion by ductal adenocarcinoma of the pancreas. J. Surg. Oncol. 65, 164-170 (1997). (Pubitemid 27351703)
29. Ceyhan, G. O. et al. Nerve growth factor and artemin are paracrine mediators of pancreatic neuropathy in pancreatic adenocarcinoma. Ann. Surg. 251, 923-931 (2010).
30. Stolinski, C. Structure and composition of the outer connective tissue sheaths of peripheral nerve. J. Anat. 186, 123-130 (1995).
31. Badger, S. A. et al. The role of surgery for pancreatic cancer: a 12-year review of patient outcome. Ulster Med. J. 79, 70-75 (2010).
32. Chen, J. W. et al. Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB (Oxford) 12, 101-108 (2010).
33. Garcea, G. et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 9, 99-132 (2008). (Pubitemid 351611725)
34. Meduri, F. et al. Pancreatic cancer and retroperitoneal neural tissue invasion. Its implication for survival following radical surgery. Zentralbl. Pathol. 140, 277-279 (1994).
35. Mossner, J. What's new in therapy of pancreatic cancer? Dig. Dis. 28, 679-683 (2010).
36. Perini, M. V. et al. Clinical and pathologic prognostic factors for curative resection for pancreatic cancer. HPB (Oxford) 10, 356-362 (2008).
37. Dai, H. et al. Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum. Pathol. 38, 299-307 (2007). (Pubitemid 46096556)
38. Gil, Z. et al. Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J. Natl Cancer Inst. 102, 107-118 (2010).
39. Ketterer, K. et al. Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer. Clin. Cancer Res. 9, 5127-5136 (2003). (Pubitemid 37413561)
40. Zhu, Z. et al. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J. Clin. Oncol. 17, 2419-2428 (1999). (Pubitemid 29368241)
41. Okada, Y., Eibl, G., Duffy, J. P., Reber, H. A. & Hines, O. J. Glial cell-derived neurotrophic factor upregulates the expression and activation of matrix metalloproteinase-9 in human pancreatic cancer. Surgery 134, 293-299 (2003). (Pubitemid 37070352)
42. Okada, Y. et al. Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells. Clin. Exp. Metastasis 21, 285-292 (2004). (Pubitemid 39434538)
43. Marchesi, F. et al. The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 68, 9060-9069 (2008).
44. Singh, P. K. et al. Platelet-derived growth factor receptor β-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res. 67, 5201-5210 (2007). (Pubitemid 46997258)
45. Swanson, B. J. et al. MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Res. 67, 10222-10229 (2007). (Pubitemid 350070795)
46. Miknyoczki, S. J. et al. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. Int. J. Cancer 81, 417-427 (1999). (Pubitemid 29165201)
47. Schneider, M. B. et al. Expression of nerve growth factors in pancreatic neural tissue and pancreatic cancer. J. Histochem. Cytochem. 49, 1205-1210 (2001). (Pubitemid 32885383)
48. Reichardt, L. F. Neurotrophin-regulated signalling pathways. Phil. Trans. R. Soc. B 361, 1545-1564 (2006). (Pubitemid 44450210)
49. Arevalo, J. C. & Wu, S. H. Neurotrophin signaling: many exciting surprises! Cell. Mol. Life Sci. 63, 1523-1537 (2006). (Pubitemid 44156749)
50. Schweigreiter, R. The dual nature of neurotrophins. Bioessays 28, 583-594 (2006). (Pubitemid 43886184)
51. Patapoutian, A. & Reichardt, L. F. Trk receptors: mediators of neurotrophin action. Curr. Opin. Neurobiol. 11, 272-280 (2001). (Pubitemid 32524091)
52. Barker, P. A. p75NTR: a study in contrasts. Cell Death Differ. 5, 346-56 (1998).
53. Chao, M. V. The p75 neurotrophin receptor. J. Neurobiol. 25, 1373-1385 (1994). (Pubitemid 24325063)
54. Hempstead, B. L. The many faces of p75NTR. Curr. Opin. Neurobiol. 12, 260-267 (2002).
55. Cornell, R. J., Rowley, D., Wheeler, T., Ali, N. & Ayala, G. Neuroepithelial interactions in prostate cancer are enhanced in the presence of prostatic stroma. Urology 61, 870-875 (2003). (Pubitemid 36384998)
56. Malin, S. A., Davis, B. M. & Molliver, D. C. Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity. Nature Protoc. 2, 152-160 (2007). (Pubitemid 47040078)
57. Tonge, D. A. et al. Effects of extracellular matrix components on axonal outgrowth from peripheral nerves of adult animals in vitro. Exp. Neurol. 146, 81-90 (1997). (Pubitemid 27319722)
58. Klesse, L. J., Meyers, K. A., Marshall, C. J. & Parada, L. F. Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells. Oncogene 18, 2055-2068 (1999).
59. Zhu, Z. et al. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Mol. Carcinog. 35, 138-147 (2002). (Pubitemid 35266060)
60. Ma, J., Jiang, Y., Sun, Y. & Zhao, X. Expression of nerve growth factor and tyrosine kinase receptor A and correlation with perineural invasion in pancreatic cancer. J. Gastroenterol. Hepatol. 23, 1852-1859 (2008).
61. Miknyoczki, S. J. et al. The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. Clin. Cancer Res. 8, 1924-1931 (2002). (Pubitemid 34633755)
62. Zhu, Z. W. et al. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells. Clin. Cancer Res. 7, 105-112 (2001).
63. Friess, H. et al. Nerve growth factor and its high-affinity receptor in chronic pancreatitis. Ann. Surg. 230, 615-624 (1999). (Pubitemid 30191822)
64. Dang, C., Zhang, Y., Ma, Q. & Shimahara, Y. Expression of nerve growth factor receptors is correlated with progression and prognosis of human pancreatic cancer. J. Gastroenterol. Hepatol. 21, 850-858 (2006). (Pubitemid 43793283)
65. Wang, W. et al. Patterns of expression and function of the p75(NGFR) protein in pancreatic cancer cells and tumours. Eur. J. Surg. Oncol. 35, 826-832 (2009).
66. Sclabas, G. M. et al. Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin. Cancer Res. 11, 440-449 (2005). (Pubitemid 40116865)
67. Airaksinen, M. S. & Saarma, M. The GDNF family: signalling, biological functions and therapeutic value. Nature Rev. Neurosci. 3, 383-394 (2002). (Pubitemid 135706635)
68. Takahashi, M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 12, 361-373 (2001). (Pubitemid 32851748)
69. Ito, Y. et al. Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers. Surgery 138, 788-794 (2005). (Pubitemid 41546203)
70. Balkwill, F. Cancer and the chemokine network. Nature Rev. Cancer 4, 540-550 (2004). (Pubitemid 38868623)
71. Hedin, K. E. Chemokines: new, key players in the pathobiology of pancreatic cancer. Int. J. Gastrointest. Cancer 31, 23-29 (2002). (Pubitemid 36330104)
72. Marchesi, F. et al. Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J. Neuroimmunol. 224, 39-44 (2010).
73. Verge, G. M. et al. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur. J. Neurosci. 20, 1150-1160 (2004). (Pubitemid 39233569)
74. Muller, M. W. et al. Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer. Int. J. Cancer 121, 2421-2433 (2007). (Pubitemid 350022411)
75. Bloomston, M., Zervos, E. E. & Rosemurgy, A. S. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann. Surg. Oncol. 9, 668-674 (2002). (Pubitemid 34857984)
76. Takahashi, H. et al. Antiproteases in preventing the invasive potential of pancreatic cancer cells. JOP 8, 501-508 (2007). (Pubitemid 47263692)
77. Pryczynicz, A., Guzinska-Ustymowicz, K., Dymicka-Piekarska, V., Czyzewska, J. & Kemona, A. Expression of matrix metalloproteinase 9 in pancreatic ductal carcinoma is associated with tumor metastasis formation. Folia Histochem. Cytobiol. 45, 37-40 (2007). (Pubitemid 46416518)
78. Zhi, Y. H., Song, M. M., Wang, P. L., Zhang, T. & Yin, Z. Y. Suppression of matrix metalloproteinase-2 via RNA interference inhibits pancreatic carcinoma cell invasiveness and adhesion. World J. Gastroenterol. 15, 1072-1078 (2009).
79. Okada, Y. et al. Experimental implication of celiac ganglionotropic invasion of pancreatic-cancer cells bearing c-ret proto-oncogene with reference to glial-cell-line-derived neurotrophic factor (GDNF). Int. J. Cancer 81, 67-73 (1999). (Pubitemid 29124199)
80. Koide, N. et al. Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer. Clin. Cancer Res. 12, 2419-2426 (2006).
81. Hustinx, S. R. et al. Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer Biol. Ther. 3, 1254-1261 (2004). (Pubitemid 41350962)
82. Nagata, S. et al. CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Ann. Surg. Oncol. 16, 2531-2538 (2009).
83. Abiatari, I. et al. Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol. Cancer Ther. 8, 1494-1504 (2009).
84. Corson, T. W., Huang, A., Tsao, M. S. & Gallie, B. L. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 24, 4741-4753 (2005). (Pubitemid 41076292)
85. Carleton, M. et al. RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failure. Mol. Cell. Biol. 26, 3853-3863 (2006). (Pubitemid 43726402)
86. Harding, M. A. & Theodorescu, D. RhoGDI signaling provides targets for cancer therapy. Eur. J. Cancer 46, 1252-1259 (2010).
87. Zhang, B., Zhang, Y., Dagher, M. C. & Shacter, E. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res. 65, 6054-6062 (2005). (Pubitemid 40994389)
88. Zhang, Y. & Zhang, B. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness. Cancer Res. 66, 5592-5598 (2006). (Pubitemid 43927109)
89. Li, Z. et al. Overexpression of synuclein-γ in pancreatic adenocarcinoma. Cancer 101, 58-65 (2004).
90. Hibi, T. et al. Synuclein-γ is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer. Clin. Cancer Res. 15, 2864-2871 (2009).
91. Ahmad, M., Attoub, S., Singh, M. N., Martin, F. L. & El-Agnaf, O. M. γ-synuclein and the progression of cancer. FASEB J. 21, 3419-3430 (2007).
92. Trapp, B. D., Andrews, S. B., Cootauco, C. & Quarles, R. The myelin-associated glycoprotein is enriched in multivesicular bodies and periaxonal membranes of actively myelinating oligodendrocytes. J. Cell Biol. 109, 2417-2426 (1989). (Pubitemid 19282626)
93. Kameda, K. et al. Expression of highly polysialylated neural cell adhesion molecule in pancreatic cancer neural invasive lesion. Cancer Lett. 137, 201-207 (1999). (Pubitemid 29179464)
94. Schreiber, S. C. et al. Polysialylated NCAM represses E-cadherin-mediated cell-cell adhesion in pancreatic tumor cells. Gastroenterology 134, 1555-1566 (2008). (Pubitemid 351615366)
95. Tezel, E., Kawase, Y., Takeda, S., Oshima, K. & Nakao, A. Expression of neural cell adhesion molecule in pancreatic cancer. Pancreas 22, 122-125 (2001). (Pubitemid 32179165)
96. Ben, Q. W. et al. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 17, 2213-2221 (2010).
97. Demir, I. E. et al. The microenvironment in chronic pancreatitis and pancreatic cancer induces neuronal plasticity. Neurogastroenterol. Motil. 22, 480-490, e112-e113 (2010).
98. Lussier, D., Huskey, A. G. & Portenoy, R. K. Adjuvant analgesics in cancer pain management. Oncologist 9, 571-591 (2004). (Pubitemid 39332322)
99. Mantyh, P. W., Clohisy, D. R., Koltzenburg, M. & Hunt, S. P. Molecular mechanisms of cancer pain. Nature Rev. Cancer 2, 201-209 (2002). (Pubitemid 37328789)
100. de Leon-Casasola, O. A. Critical evaluation of chemical neurolysis of the sympathetic axis for cancer pain. Cancer Control 7, 142-148 (2000). (Pubitemid 30196851)
101. Kaufman, M. et al. Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer. J. Clin. Gastroenterol. 44, 127-134 (2010).
102. Vranken, J. H., Zuurmond, W. W. & de Lange, J. J. Increasing the efficacy of a celiac plexus block in patients with severe pancreatic cancer pain. J. Pain Symptom Manage. 22, 966-977 (2001). (Pubitemid 33111998)
103. Yang, I. Y. & Oraee, S. A modified approach to transcrural celiac plexus block. Reg. Anesth. Pain Med. 30, 303-307 (2005). (Pubitemid 40718915)
104. di Mola, F. F. & di Sebastiano, P. Pain and pain generation in pancreatic cancer. Langenbecks Arch. Surg. 393, 919-922 (2008).
105. Lindsay, T. H. et al. Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. Pain 119, 233-246 (2005). (Pubitemid 41752984)
106. Zhu, Y. et al. Nerve growth factor modulates TRPV1 expression and function and mediates pain in chronic pancreatitis. Gastroenterology 141, 370-377 (2011).
107. Nilius, B., Owsianik, G., Voets, T. & Peters, J. A. Transient receptor potential cation channels in disease. Physiol. Rev. 87, 165-217 (2007). (Pubitemid 46207713)
108. Jara-Oseguera, A., Simon, S. A. & Rosenbaum, T. TRPV1: on the road to pain relief. Curr. Mol. Pharmacol. 1, 255-269 (2008).
109. Hartel, M. et al. Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut 55, 519-528 (2006).
110. Pingle, S. C., Matta, J. A. & Ahern, G. P. Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb. Exp. Pharmacol. 179, 155-171 (2007).
111. Anand, U. et al. The effect of neurotrophic factors on morphology, TRPV1 expression and capsaicin responses of cultured human DRG sensory neurons. Neurosci. Lett. 399, 51-56 (2006).
112. Liddle, R. A. The role of transient receptor potential vanilloid 1 (TRPV1) channels in pancreatitis. Biochim. Biophys. Acta 1772, 869-878 (2007). (Pubitemid 47176372)
113. Amaya, F. et al. NGF and GDNF differentially regulate TRPV1 expression that contributes to development of inflammatory thermal hyperalgesia. Eur. J. Neurosci. 20, 2303-2310 (2004). (Pubitemid 39472393)
114. Malin, S. A. et al. Glial cell line-derived neurotrophic factor family members sensitize nociceptors in vitro and produce thermal hyperalgesia in vivo. J. Neurosci. 26, 8588-8599 (2006). (Pubitemid 44316188)
115. Schweizerhof, M. et al. Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nature Med. 15, 802-807 (2009).
116. Stosser, S., Schweizerhof, M. & Kuner, R. Hematopoietic colony-stimulating factors: new players in tumor-nerve interactions. J. Mol. Med. 89, 321-329 (2011).
117. Abdiche, Y. N., Malashock, D. S. & Pons, J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci. 17, 1326-1335 (2008).
118. Hefti, F. F. et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol. Sci. 27, 85-91 (2006). (Pubitemid 43184029)
119. Lane, N. E. et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363, 1521-1531 (2010).
120. Watson, J. J., Allen, S. J. & Dawbarn, D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs 22, 349-359 (2008).
121. Wood, J. N. Nerve growth factor and pain. N. Engl. J. Med. 363, 1572-1573 (2010).
122. Cattaneo, A. et al. Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody. J. Neurosci. 19, 9687-9697 (1999). (Pubitemid 30226642)
123. Covaceuszach, S., Cattaneo, A. & Lamba, D. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight. Proteins 58, 717-727 (2005). (Pubitemid 40176043)
124. Ugolini, G., Marinelli, S., Covaceuszach, S., Cattaneo, A. & Pavone, F. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc. Natl Acad. Sci. USA 104, 2985-2990 (2007). (Pubitemid 46327990)
125. Wehrman, T. et al. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron 53, 25-38 (2007). (Pubitemid 44969482)
126. Watson, J. J. et al. TrkAd5: a novel therapeutic agent for treatment of inflammatory pain and asthma. J. Pharmacol. Exp. Ther. 316, 1122-1129 (2006). (Pubitemid 43345286)
127. Dawbarn, D. et al. NGF receptor TrkAd5: therapeutic agent and drug design target. Biochem. Soc. Trans. 34, 587-590 (2006).
128. Sutherland, S. Peptibodies: the new cool technology. Drug Discov. Today 9, 683 (2004). (Pubitemid 39070275)
129. Wang, T., Yu, D. & Lamb, M. L. Trk kinase inhibitors as new treatments for cancer and pain. Expert Opin. Ther. Pat. 19, 305-319 (2009).
130. Wood, E. R. et al. Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg. Med. Chem. Lett. 14, 953-957 (2004). (Pubitemid 38167620)
131. Ghilardi, J. R. et al. Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers. Bone 48, 389-398 (2011).
132. Tibes, R. et al. Phase I dose escalation study of the oral multi-CDK inhibitor PHA-848125. J. Clin. Oncol. 26 (Suppl., Abstract 3531 (2008).
133. Brasca, M. G. et al. Identification of N-1,4,4-tetramethyl-8-{[4-(4- methylpiperazin-1-yl)phenyl]amino}-4,5-dihydr o-1H-pyrazolo[4,3-h]quinazoline-3- carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J. Med. Chem. 52, 5152-5163 (2009).
134. Caporali, S. et al. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound. Pharmacol. Res. 61, 437-448 (2010).
135. Degrassi, A. et al. Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging. Mol. Cancer Ther. 9, 673-681 (2010).
136. Albanese, C. et al. Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. Mol. Cancer Ther. 9, 2243-2254 (2010).
137. Premkumar, L. S. Targeting TRPV1 as an alternative approach to narcotic analgesics to treat chronic pain conditions. AAPS J. 12, 361-370 (2010).
138. Wong, G. Y. & Gavva, N. R. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res. Rev. 60, 267-277 (2009).
139. Ghilardi, J. R. et al. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J. Neurosci. 25, 3126-3131 (2005). (Pubitemid 40463547)
140. Dorgham, K. et al. An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. J. Leukoc. Biol. 86, 903-911 (2009).
141. Yin, Q., Cheng, W., Cheng, M. Y., Fan, S. Z. & Shen, W. Intrathecal injection of anti-CX3CR1 neutralizing antibody delayed and attenuated pain facilitation in rat tibial bone cancer pain model. Behav. Pharmacol. 21, 595-601 (2010).
142. Cameron, J. L. et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am. J. Surg. 161, 120-124 (1991).
143. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
144. Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. & Depinho, R. A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218-1249 (2006). (Pubitemid 43727584)
145. Kayahara, M. et al. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 72, 2118-2123 (1993). (Pubitemid 23280135)
146. Shimada, K. et al. Intrapancreatic nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with invasive ductal carcinoma of the pancreas. Pancreas 40, 464-468 (2011).
147. Samkharadze, T. et al. Pigment epithelium-derived factor associates with neuropathy and fibrosis in pancreatic cancer. Am. J. Gastroenterol. 106, 968-980 (2011).
148. Guerra, C. et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291-302 (2007). (Pubitemid 46349841)
149. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003). (Pubitemid 38050041)
150. Freelove, R. & Walling, A. D. Pancreatic cancer: diagnosis and management. Am. Fam. Physician 73, 485-492 (2006). (Pubitemid 43211735)
151. Kang, S. P. & Saif, M. W. Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP 9, 83-90 (2008). (Pubitemid 351611723)
152. Burris, H. A. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413 (1997).
153. Campen, C. J., Dragovich, T. & Baker, A. F. Management strategies in pancreatic cancer. Am. J. Health Syst. Pharm. 68, 573-584 (2011).
154. Di Marco, M. et al. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? Oncol. Rep. 23, 1183-1192 (2010).
155. Fung, M. C. & Sakata, T. What's new in pancreatic cancer treatment? J. Hepatobiliary Pancreat. Surg. 9, 61-75 (2002). (Pubitemid 34477372)
156. Li, J. & Saif, M. W. Advancements in the management of pancreatic cancer. JOP 10, 109-117 (2009).
157. Sharma, C. et al. Adjuvant therapy of pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-4, 2011. JOP 12, 343-346 (2011).
158. Helm, J. et al. Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer. Cancer 115, 4080-4089 (2009).
159. Pawlik, T. M. et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141, 610-618 (2007). (Pubitemid 46616937)
160. Washington, K. et al. Protocol for the examination of specimens from patients with carcinoma of the exocrine pancreas: protocol applies to all epithelial tumors of the exocrine pancreas. endocrine tumors and tumors of the ampulla of vater are not included. College of American Pathologists [online], http://www.cap.org/apps/docs/committees/cancer/cancer-protocols/2009/ PancreasExo-09protocol.pdf (2009).